B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.